| Literature DB >> 30747911 |
Anahit Babayan1,2, Miray Erbey1,2,3, Deniz Kumral1,2, Janis D Reinelt1, Andrea M F Reiter1,4,5,6, Josefin Röbbig1, H Lina Schaare1,4, Marie Uhlig1,4, Alfred Anwander7, Pierre-Louis Bazin1,8,9, Annette Horstmann1,10, Leonie Lampe1, Vadim V Nikulin1, Hadas Okon-Singer1,11, Sven Preusser1, André Pampel12, Christiane S Rohr1, Julia Sacher1, Angelika Thöne-Otto1,13, Sabrina Trapp1, Till Nierhaus1, Denise Altmann1, Katrin Arelin1, Maria Blöchl4,14, Edith Bongartz1, Patric Breig1, Elena Cesnaite1, Sufang Chen1, Roberto Cozatl15, Saskia Czerwonatis1, Gabriele Dambrauskaite1, Maria Dreyer1, Jessica Enders1, Melina Engelhardt1, Marie Michele Fischer1, Norman Forschack1, Johannes Golchert16, Laura Golz1, C Alexandrina Guran1, Susanna Hedrich1, Nicole Hentschel1, Daria I Hoffmann1, Julia M Huntenburg16, Rebecca Jost1, Anna Kosatschek1, Stella Kunzendorf1, Hannah Lammers1, Mark E Lauckner16, Keyvan Mahjoory1, Ahmad S Kanaan12, Natacha Mendes16, Ramona Menger1, Enzo Morino1, Karina Näthe17, Jennifer Neubauer1, Handan Noyan1, Sabine Oligschläger16, Patricia Panczyszyn-Trzewik1, Dorothee Poehlchen1, Nadine Putzke1, Sabrina Roski1, Marie-Catherine Schaller1, Anja Schieferbein1, Benito Schlaak1, Robert Schmidt18, Krzysztof J Gorgolewski19, Hanna Maria Schmidt1, Anne Schrimpf1, Sylvia Stasch1, Maria Voss1, Annett Wiedemann1, Daniel S Margulies16, Michael Gaebler1,2,20, Arno Villringer1,2.
Abstract
We present a publicly available dataset of 227 healthy participants comprising a young (N=153, 25.1±3.1 years, range 20-35 years, 45 female) and an elderly group (N=74, 67.6±4.7 years, range 59-77 years, 37 female) acquired cross-sectionally in Leipzig, Germany, between 2013 and 2015 to study mind-body-emotion interactions. During a two-day assessment, participants completed MRI at 3 Tesla (resting-state fMRI, quantitative T1 (MP2RAGE), T2-weighted, FLAIR, SWI/QSM, DWI) and a 62-channel EEG experiment at rest. During task-free resting-state fMRI, cardiovascular measures (blood pressure, heart rate, pulse, respiration) were continuously acquired. Anthropometrics, blood samples, and urine drug tests were obtained. Psychiatric symptoms were identified with Standardized Clinical Interview for DSM IV (SCID-I), Hamilton Depression Scale, and Borderline Symptoms List. Psychological assessment comprised 6 cognitive tests as well as 21 questionnaires related to emotional behavior, personality traits and tendencies, eating behavior, and addictive behavior. We provide information on study design, methods, and details of the data. This dataset is part of the larger MPI Leipzig Mind-Brain-Body database.Entities:
Mesh:
Year: 2019 PMID: 30747911 PMCID: PMC6371893 DOI: 10.1038/sdata.2018.308
Source DB: PubMed Journal: Sci Data ISSN: 2052-4463 Impact factor: 6.444
Figure 1Overview of data acquisition.
Measures are listed in their order of acquisition and time duration on each assessment day.
Exclusion criteria.
| Exclusion criteria via telephone screening: Self-reported |
|---|
| ► Diagnosis of hypertension without intake of antihypertensive medication |
| ► Any other cardiovascular disease (current and/or previous heart attack or congenital heart defect) |
| ► History of psychiatric diseases that required inpatient treatment for longer than 2 weeks, within the last 10 years (psychosis, attempted suicide, post-traumatic stress disorder) |
| ► History of neurological disorders (multiple sclerosis, stroke, epilepsy, brain tumor, meningoencephalitis, severe concussion) |
| ► History of malignant diseases |
| ► Intake of one of the following medications (centrally active medication, beta- and alpha-blocker, cortisol, any chemotherapeutic or psychopharmacological medication) |
| ► Positive drug anamnesis (extensive alcohol, MDMA, amphetamines, cocaine, opiates, benzodiazepine, cannabis) |
| ► MRI exclusion criteria (metallic implants, braces, non-removable piercings, tattoos, pregnancy, claustrophobia, tinnitus, surgical operation in the last 3 months) |
| ► Previous participation in any scientific study within the last 10 years |
| ► Previous or current enrollment in undergraduate, graduate or postgraduate psychology studies |
Overview of Measures and Data Availability for Day 0 and Day 1.
| Days | Assessments | Details | n |
|---|---|---|---|
| BP1 = Blood Pressure measured before scan, BP2 = Blood Pressure measured after scan, CVLT = California Verbal Learning Task, DWI = Diffusion-weighted imaging, ECG = Electrocardiography, EDTA full blood = Ethylenediaminetetraacetic acid in full blood, FLAIR (2D) = Fluid-attenuated inversion recovery (2 Dimensional), FLAIR (3D) = Fluid-attenuated inversion recovery (3 Dimensional), LPS-2 (Subtest 3) = Subtest 3 of the “Leistungsprüfsystem 2”, MDBF = Multidimensional Mood State Questionnaire, MP2RAGE = Magnetization-Prepared 2 Rapid Acquisition Gradient Echoes, NYC-Q = New York Cognition Questionnaire, RNA = Ribonucleic acid, rsfMRI = Resting-state Magnetic Resonance Imaging, RWT = Regensburger Wortflüssigkeitstest, SWI = T2*/susceptibility-weighted imaging, QSM = quantitative susceptibility mapping, T2-weighted = Spin-Spin-Relaxation imaging, TAP = Test of Attentional Performance, TMT = Trail Making Test, WST = Wortschatztest. | |||
| Participant Enrollment Day 0 | Telephone Screening/study and MRI/ Medical briefing | Inclusion | n=227 |
| Exclusion | n=468 | ||
| Assessment Day 1 | Cognitive Test Battery | CVLT | n=228 |
| TAP | n=227 | ||
| TMT | n=227 | ||
| WST | n=227 | ||
| LPS-2 (Subtest 3) | n=227 | ||
| RWT | n=227 | ||
| Mood Questionnaire | MDBF (Day 1) | n=227 | |
| Blood Pressure 1 | BP1 (left) | n=225 | |
| Pulse1 (left) | n=223 | ||
| BP1 (right) | n=223 | ||
| Pulse1 (right) | n=222 | ||
| Peripheral physiological recordings during rs-fMRI | ECG | n=213 | |
| Blood pressure (beat-to-beat) | n=143 | ||
| Pulse (Photoplethysmography) | n=143 | ||
| Respiration | n=162 | ||
| MRI | Fieldmap for rs-fMRI | n=226 | |
| Spin echo images with reversed phase encoding direction (2 pairs) for rs-fMRI | n=226 | ||
| rs-fMRI | n=226 | ||
| MP2RAGE | n=226 | ||
| T2-weighted | n=224 | ||
| FLAIR (2D) | n=110 | ||
| FLAIR (3D) | n=115 | ||
| DWI (in first 112 participants) | n=110 | ||
| Spin echo images with reversed phase encoding direction (2 pairs) for DWI (in first 112 participants) | n=110 | ||
| DWI (after 112 participants) | n=115 | ||
| Spin echo images with reversed phase encoding direction (2 pairs) for DWI (after 112 participants) | n=115 | ||
| SWI and QSM | n=111 | ||
| Mind Wandering Questionnaire | NYC-Q | n=227 | |
| Blood Pressure 2 | BP2 (left) | n=225 | |
| Pulse2 (left) | n=225 | ||
| Peripheral Blood Sample Laboratory Analysis | Electrolytes: Sodium (NA+), Potassium (K), Chloride (Cl-) | n=217 | |
| Liver: Alanine transaminase (ALAT), asparate transaminase (ASAT), Gamma-glutamyltransferase (GGT) | n=217 | ||
| Kidney: Creatinine | n=217 | ||
| Lipid metabolism: Cholesterol, High density lipoprotein cholesterol (HDL), Low density lipoprotein cholesterol (LDL), triglycerides | n=217 | ||
| Inflammatory mediators: C-reactive protein (CRP) | n=217 | ||
| Thyroid gland: Thyreotropin/ Thyroid-stimulating hormone (TSH) | n=217 | ||
| Glucose (not fasting), Glycated hemoglobin (HbA1c; NSGP/DCCT), Glycated hemoglobin (HbA1c; IFCC) | n=215 | ||
| Complete Blood cell Count (CBC) without differential | n=213 | ||
| Prothrombin time (PT) & International normalized ratio (INR) | n=211 | ||
| Frozen Blood Sample | Serum (Frozen Samples) | n=220 | |
| EDTA full blood (Frozen Aliquots) | n=217 | ||
| Blood Sample in RNA tubes (Frozen Samples) | n=211 | ||
| Anthropometry | Body weight | n=227 | |
| Body height | n=227 | ||
| Waist and hip circumference | n=227 | ||
| Hair Sample | Hair 4 cm | n=177 | |
Overview of Measures and Data Availability for Day 2.
| Days | Assessments | Details | n |
|---|---|---|---|
| AUDIT=Alcohol Use Disorder Identification Test, BIS/BAS=Behavioral Inhibition and Approach System, BSL-23=Borderline Symptoms List (short version), CERQ=Cognitive Emotion Regulation Questionnaire, COPE=Coping Orientations to Problems Experienced, CVLT=California Verbal Learning Task, DWI=Diffusion-weighted imaging, ECG=Electrocardiography, EDTA full blood=Ethylenediaminetetraacetic acid in full blood, ERQ=Emotion Regulation Questionnaire, F-SoZU K-22=Social Support Questionnaire, FEV=Eating Behavior, FLAIR (2D)=Fluid-attenuated inversion recovery (2 Dimensional), FLAIR (3D)=Fluid-attenuated inversion recovery (3 Dimensional), FTP=Future Time Perspective Questionnaire, HAM-D=Hamilton Depression scale (HAM-D), LOT-R=Optimism Pessimism Questionnaire-Revised, MARS=Affect Regulation Style, MDBF=Multidimensional Mood State Questionnaire, MP2RAGE=Magnetization-Prepared 2 Rapid Acquisition Gradient Echoes, MSPSS=Multidimensional Scale of Perceived Social Support, NEO-FFI=Big-Five of Personality, PSQ=Perceived Stress Questionnaire, RNA=Ribonucleic acid, RsEEG=Resting-state electroencephalogram, STAI-G-X2=State-Trait Anxiety Inventory (short version), STAXI=State-Trait Anger Expression Inventory, TAS-26=Toronto-Alexithymia Scale, TEIQue-SF=Emotional Intelligence Questionnaire, TICS=Trier Inventory of Chronic Stress, UPPS=Impulsivity Questionnaires, YFAS=Addicted Eating Behavior. | |||
| Assessment Day 2 | Mood Questionnaire | MDBF (Day 2) | n=218 |
| EEG | Raw rs-EEG (Brain Products ActiCaps) | n=217 | |
| Preprocessed rs-EEG | n=202 | ||
| Digitized EEG channel locations | n=144 | ||
| Drug Test | Multi 8/2 Drogentest | n=220 | |
| Emotion and Personality Battery | ERQ | n=220 | |
| CERQ | n=220 | ||
| PSQ | n=220 | ||
| TICS | n=220 | ||
| COPE | n=219 | ||
| LOT-R | n=220 | ||
| STAXI | n=220 | ||
| NEO-FFI | n=220 | ||
| STAI-G-X2 | n=220 | ||
| FEV | n=220 | ||
| YFAS | n=169 | ||
| BIS/BAS | n=220 | ||
| UPPS | n=220 | ||
| TAS-26 | n=220 | ||
| MARS | n=208 | ||
| F-SozU K-22 | n=220 | ||
| MSPSS | n=220 | ||
| TEIQue-SF | n=220 | ||
| Psychiatric screening | SCID I | n=219 | |
| HAM-D | n=218 | ||
| AUDIT | n=219 | ||
| BSL-23 | n=169 | ||
Follow-up assessment days.
| Days | Assessments | Details | n | |
|---|---|---|---|---|
| AP=anterior-posterior phase encoding acquisition (rs-fMRI), BP3 = Blood Pressure measured on follow-up assessment day, FTP = Future Time Perspective Questionnaire, MDBF = Multidimensional Mood State Questionnaire, PA=posterior- anterior hase encoding acquisition (rs-fMRI). | ||||
| Blood Pressure 3 | BP3 (left) | n=159 | ||
| Future Time Perspective Questionnaire | FTP | n=141 | ||
| Mood Questionnaire | MBDF (Day 3) | n=159 | ||
| Blood Pressure | BP1 (left) | n=91 | ||
| Pulse1 (left) | n=44 | |||
| Peripheral physiological recordings during rs-fMRI of participants in LEMON and Mendes | ECG | rs-fMRI 1 (AP-run1) | n=98 | |
| rs-fMRI 2 (PA-run1) | n=97 | |||
| rs-fMRI 3 (AP-run2) | n=94 | |||
| rs-fMRI 4 (PA-run2) | n=90 | |||
| Blood pressure (beat-to-beat) | rs-fMRI 1 (AP-run1) | n=101 | ||
| rs-fMRI 2 (PA-run1) | n=101 | |||
| rs-fMRI 3 (AP-run2) | n=97 | |||
| rs-fMRI 4 (PA-run2) | n=91 | |||
| Pulse (Photoplethysmography) | rs-fMRI 1 (AP-run1) | n=101 | ||
| rs-fMRI 2 (PA-run1) | n=101 | |||
| rs-fMRI 3 (AP-run2) | n=97 | |||
| rs-fMRI 4 (PA-run2) | n=91 | |||
| Respiration | rs-fMRI 1 (AP-run1) | n=98 | ||
| rs-fMRI 2 (PA-run1) | n=97 | |||
| rs-fMRI 3 (AP-run2) | n=94 | |||
| rs-fMRI 4 (PA-run2) | n=90 | |||
| Additional peripheral physiological recordings during rs-fMRI of participants in Mendes | ECG | rs-fMRI 1 (AP-run1) | n=86 | |
| rs-fMRI 2 (PA-run1) | n=84 | |||
| rs-fMRI 3 (AP-run2) | n=80 | |||
| rs-fMRI 4 (PA-run2) | n=74 | |||
| Blood pressure (beat-to-beat) | rs-fMRI 1 (AP-run1) | n=79 | ||
| rs-fMRI 2 (PA-run1) | n=76 | |||
| rs-fMRI 3 (AP-run2) | n=74 | |||
| rs-fMRI 4 (PA-run2) | n=67 | |||
| Pulse (Photoplethys-mography) | rs-fMRI 1 (AP-run1) | n=79 | ||
| rs-fMRI 2 (PA-run1) | n=76 | |||
| rs-fMRI 3 (AP-run2) | n=74 | |||
| rs-fMRI 4 (PA-run2) | n=67 | |||
| Respiration | rs-fMRI 1 (AP-run1) | n=86 | ||
| rs-fMRI 2 (PA-run1) | n=84 | |||
| rs-fMRI 3 (AP-run2) | n=80 | |||
| rs-fMRI 4 (PA-run2) | n=74 | |||
Cognitive test battery.
| Name | Full Name | Reference | Measured construct |
|---|---|---|---|
| These tests are completed in a fixed order on assessment day 1. | |||
| CVLT-part 1 | California Verbal Learning Task | Niemann | Verbal learning, memory |
| TAP Alertness | Test of Attentional Performance: Alertness | Zimmermann & Fimm[ | Alertness, general wakefulness |
| TAP Incompatibility | Test of Attentional Performance: Incompatibility | Zimmermann & Fimm[ | Interference |
| TAP Working Memory | Test of Attentional Performance: Memory | Zimmermann & Fimm[ | Working memory |
| TMT A | Trail Making Test | Reitan[ | Visuomotor speed |
| TMT B | Trail Making Test | Reitan[ | Executive function |
| CVLT-part 2 | California Verbal Learning Task | Niemann | Verbal learning, memory |
| WST | Wortschatztest | Schmidt & Metzler[ | Verbal intelligence, crystallized intelligence |
| LPS-2, subtest 3 | Subtest 3 of the “Leistungsprüfsystem 2” | Kreuzpointner | Fluid intelligence |
| RWT S-Words | Regensburger Wortflüssigkeitstest: S-words | Aschenbrenner | Verbal fluency |
| RWT Animals | Regensburger Wortflüssigkeitstest: Animals | Aschenbrenner | Verbal fluency |
Emotion and personality test battery with their reliability measures.
| Abbr. | Full Name | Reference | Items | Measured construct | M (±SD) | Cronbach's alpha | ||
|---|---|---|---|---|---|---|---|---|
| Original | LEMON | |||||||
| aScores on these 7 questionnaires have been calculated as mean scores (NEO- FFI, ERQ, MARS, F-SozU K-22, PSQ standardized means, TEIQue-SF subscales, FTP). All the rest are calculated as sum scores. | ||||||||
| bSymptom counts indicate how many of 7 YFAS-criteria were fulfilled (range 0–7). | ||||||||
| cInternal consistency based on Kuder-Richardson’s alpha coefficient (Meule & Gearhardt,[ | ||||||||
| Note: These first 18 questionnaires are completed in randomized order on a computer (LimeSurvey) on assessment day 2. The last three questionnaires (19–21) are completed as paper and pen version on a follow-up assessment day. | ||||||||
| 1 | Neo Five Factor Inventory | Costa & McCrae[ | 60 | Neuroticism | 1.5 (±0.6) | 0.87 | 0.81 | |
| Extraversion | 2.4 (±0.5) | 0.81 | 0.79 | |||||
| Openness for Experiences | 2.7 (±0.5) | 0.75 | 0.71 | |||||
| Agreeableness | 2.8 (±0.4) | 0.72 | 0.7 | |||||
| Conscientiousness | 2.7 (±0.6) | 0.84 | 0.85 | |||||
| 2 | Impulsive Behavior Scale | Whiteside & Lynam[ | 45 | Lack of Premeditation | 22.6 (±3.9) | 0.85 | 0.69 | |
| Urgency | 25.8 (±4.8) | 0.84 | 0.8 | |||||
| Sensation Seeking | 32.4 (±7.0) | 0.83 | 0.85 | |||||
| Lack of Perseverance | 19.1 (±4.7) | 0.85 | 0.83 | |||||
| 3 | Bahavioural Inhibition and Approach System | Carver & White[ | 24 | Behavioral Inhibition Score (BIS) | 19.9 (±3.1) | 0.78 | 0.68 | |
| BAS Subscale Drive | 12.0 (±2.1) | 0.69 | 0.74 | |||||
| BAS Subscale Reward Responsiveness | 16.9 (±2.0) | 0.69 | 0.54 | |||||
| BAS Subscale Fun Seeking | 12.3 (±1.7) | 0.67 | 0.47 | |||||
| 4 | Emotion Regulation Questionnaire | Gross & John[ | Reappraisal | 4.7 (±1.0) | 0.74 | 0.79 | ||
| Suppression | 3.7 (±1.2) | 0.77 | 0.71 | |||||
| 5 | Cognitive Emotion Regulation Questionnaire | Garnefski | 27 | Acceptance | 6.9 (±2.8) | 0.6 | 0.84 | |
| Positive Refocusing | 5.0 (±2.7) | 0.86 | 0.82 | |||||
| Refocusing on Planning | 8.0 (±2.6) | 0.77 | 0.78 | |||||
| Positive Reappraisal | 6.8 (±2.8) | 0.78 | 0.74 | |||||
| Putting into Perspective | 7.2 (±2.7) | 0.77 | 0.75 | |||||
| Self Blame | 4.2 (±2.3) | 0.73 | 0.7 | |||||
| Rumination | 5.4 (±2.7) | 0.66 | 0.69 | |||||
| Catastrophizing | 2.6 (±2.3) | 0.73 | 0.73 | |||||
| Blaming Others | 2.3 (±1.8) | 0.76 | 0.76 | |||||
| 6 | Meausre of Affect Regulation Style | Larsen & Prizmic[ | Behavioral Distraction | 3.1 (±0.8) | 0.75 | 0.69 | ||
| Cognitive Distraction | 3.5 (±0.9) | 0.78 | 0.67 | |||||
| Situation-focused Strategies | 3.4 (±0.9) | 0.6 | 0.63 | |||||
| Affect-focused Strategies | 2.5 (±0.9) | 0.59 | 0.65 | |||||
| Disengagement | 1.8 (±0.9) | 0.55 | 0.58 | |||||
| Avoidance | 2.5 (±0.8) | 0.51 | 0.57 | |||||
| 7 | Social Support Questionnaire | Fydrich | 22 | Emotional Support | 4.6 (±0.5) | 0.81-0.93 | 0.88 | |
| Practical Support | 4.5 (±0.6) | 0.81-0.93 | 0.79 | |||||
| Social Integration | 4.2 (±0.6) | 0.81-0.93 | 0.71 | |||||
| Availability of Trusted Person | 4.7 (±0.6) | 0.81-0.93 | 0.72 | |||||
| Satisfaction with Social Support | 3.6 (±0.9) | 0.81-0.93 | 0.58 | |||||
| 8 | Multidimensional Scale of Perceived Social Support | Zimet, G.D | 12 | Friends | 24.3 (±3.8) | 0.85 | 0.93 | |
| Family | 22.7 (±5.3) | 0.87 | 0.92 | |||||
| Significant Others | 25.2 (±3.6) | 0.91 | 0.87 | |||||
| 9 | Coping Orientations to Problems Experienced (Brief COPE) | carver[ | Self Distraction | 5.2 (±1.4) | 0.71 | 0.67 | ||
| Active Coping | 5.7 (±1.3) | 0.68 | 0.66 | |||||
| Denial | 2.1 (±1.2) | 0.54 | 0.61 | |||||
| Substance Use | 2.7 (±1.2) | 0.9 | 0.91 | |||||
| Use of Emotional Support | 5.9 (±1.5) | 0.71 | 0.78 | |||||
| Use of Instrumental Support | 5.5 (±1.7) | 0.64 | 0.91 | |||||
| Behavioral Disengagement | 3.0 (±1.0) | 0.65 | 0.21 | |||||
| Venting | 4.3 (±1.3) | 0.5 | 0.57 | |||||
| Positive Reframing | 5.5 (±1.5) | 0.64 | 0.73 | |||||
| Planning | 6.2 (±1.2) | 0.73 | 0.44 | |||||
| Humor | 4.1 (±1.6) | 0.73 | 0.68 | |||||
| Acceptance | 5.5 (±1.5) | 0.57 | 0.68 | |||||
| Religion | 2.8 (±1.4) | 0.82 | 0.69 | |||||
| Self-Blame | 4.6 (±1.5) | 0.69 | 0.75 | |||||
| 10 | Life Orientation Test – Revised | Scheier | 10 | Optimism | 8.9 (±2.3) | 0.69 | 0.75 | |
| Pessimism | 4.7 (±2.2) | 0.68 | 0.66 | |||||
| Overall Score | 27.3 (±4.8) | 0.59 | 0.62 | |||||
| 11 | Perceived Stress Questionnaire | Levenstein | 20 | Worries | 26.3 (±18.6) | 0.86 | 0.82 | |
| Tension | 28.2 (±19.0) | 0.84 | 0.83 | |||||
| Joy | 67.0 (±18.1) | 0.85 | 0.74 | |||||
| Demands | 32.9 (±20.4) | 0.8 | 0.83 | |||||
| 12 | Trier Inventory of Chronic Stress | Schulz & Schlotz[ | 57 | Work Overload | 9.5 (±6.7) | 0.9 | 0.92 | |
| Social Overload | 7.1 (±4.5) | 0.84 | 0.81 | |||||
| Pressure to Perform | 14.0 (±6.4) | 0.9 | 0.87 | |||||
| Work Discontent | 10.6 (±5.7) | 0.85 | 0.86 | |||||
| Excessive Demands at Work | 5.7 (±4.3) | 0.87 | 0.89 | |||||
| Lack of Social Recognition | 4.2 (±3.1) | 0.84 | 0.84 | |||||
| Social Tension | 5.4 (±3.7) | 0.87 | 0.86 | |||||
| Social Isolation | 6.6 (±4.6) | 0.88 | 0.86 | |||||
| Chronic Worrying | 5.3 (±3.6) | 0.88 | 0.88 | |||||
| 13 | Three-factor Eating Questionnaire | Stunkard & Messick[ | 60 | Cognitive Restraint | 6.5 (±4.7) | 0.87 | 0.86 | |
| Disinhibition | 4.8 (±2.6) | 0.82 | 0.66 | |||||
| Hunger | 4.6 (±2.9) | 0.78 | 0.71 | |||||
| 14 | Yale Food Addiction Scale | Gearhardt | 27 | YFAS Symptom Countb | 1.4 (±0.7) | 0.86 | 0.31c | |
| 15 | Emotional Intelligence Questionnaire | Petrides & Furnham[ | 30 | Well-being | 5.6 (±0.9) | 0.94 | 0.79 | |
| Self Control | 5.1 (±0.8) | 0.86 | 0.52 | |||||
| Emotionality | 5.0 (±0.8) | 0.9 | 0.61 | |||||
| Sociability | 4.9 (±0.8) | 0.88 | 0.56 | |||||
| Global Trait Emotiona Intelligence | 152.4 (±18.0) | 0.96 | 0.86 | |||||
| 16 | State-Trait Anxiety Inventory | Spielberger | 20 | Trait Anxiety | 36.3 (±8.6) | 0.88-0.94 | 0.91 | |
| 17 | Toronto Alexithymia Scale | Bagby | 26 | Difficulty with Identifying Feelings | 13.2 (±4.2) | 0.84 | 0.79 | |
| Difficulty with Expressing and Describing Feelings | 13.7 (±3.9) | 0.69 | 0.76 | |||||
| Externally-oriented Thinking | 14.4 (±3.4) | 0.67 | 0.63 | |||||
| 18 | State-Trait Anger Expression Inventory | Spielberger[ | 44 | Trait Anger | 18.3 (±4.1) | 0.88 | 0.79 | |
| Anger-In | 16.4 (±3.9) | 0.79 | 0.76 | |||||
| Anger-Out | 11.7 (±3.2) | 0.86 | 0.81 | |||||
| Anger-Control | 22.8 (±3.8) | 0.88 | 0.76 | |||||
| 19 | Multidimensional Mood State Questionnaire | Steyer | 24 | Good-Bad | 34.8 (±3.0) | 0.91-0.94 | 0.82-0.87 | |
| Awake-Tired | 31.6 (±4.6) | 0.92-0.94 | 0.92-0.93 | |||||
| Calm-Nervous | 32.8 (±3.6) | 0.86-0.91 | 0.84-0.87 | |||||
| 20 | Future Time Perspective Questionnaire | Lang and Carstensen[ | 10 | Future Time Perspective | 44.8 (±11.3) | 0.92 | 0.73 | |
| 21 | New York Cognition Questionnaire | Gorgolewski | 31 | NYC-Q Score | NA | NA | NA | |
MRI sequences.
| MRI scan | Sequence parameters | File name (raw, nifti format) | File name (preprocessed, nifti format) |
|---|---|---|---|
| Gradient echo fieldmap for rs-fMRI distortion correction | voxel size=2.3 mm isotropic, FOV=202 mm, imaging matrix=88×88, 64 slices with 2.3 mm thickness, TR= 680 ms, TE1=5.19 ms, TE2=7.65 ms, flip angle=60°, bandwidth=389 Hz/pixel, prescan normalization, no partial fourier, duration=2 min 3 s | acq-GEfmap_run-01_magnitude1, acq-GEfmap_run-01_magnitude2, acq-GEfmap_run-01_phasediff | |
| Spin echo EPI with reversed phase encoding for rs-fMRI distortion correction | voxel size=2.3 mm isotropic, FOV=202 mm, imaging matrix=88×88, 64 slices with 2.3 mm thickness, TR=2200 ms, TE=50 ms, flip angle=90°, echo spacing=0.67ms, phase encoding=A ≫ P / P ≫ A, bandwidth=1776 Hz/pixel, partial fourier 6/8, no pre-scan normalization, duration=29 s each | acq-SEfmapBOLDpost_dir-AP_epi, acq-SEfmapBOLDpost_dir-PA_epi, acq-SEfmapBOLDpre_dir-AP_epi, acq-SEfmapBOLDpre_dir-PA_epi | |
| Resting-state fMRI (T2*-weighted gradient-echo EPI BOLD) | Axial acquisition orientation, phase encoding=A ≫ P, voxel size=2.3 mm isotropic, FOV=202 mm, imaging matrix=88×88, 64 slices with 2.3 mm thickness, TR=1400 ms, TE=30 ms, flip angle=69°, echo spacing=0.67 ms, bandwidth=1776 Hz/pixel, partial fourier 7/8, no pre-scan normalization, multiband acceleration factor=4, 657 volumes, slice order=interleaved, duration=15 min 30 s | acq-AP-run-01_bold | task-rest_acq-AP_run-01_native, task-rest_acq-AP_run-01_MNI2mm |
| Magnetization Prepared 2 Rapid Acquisition Gradient Echoes (MP2RAGE) | Sagittal acquisition orientation, one 3D volume with 176 slices, TR=5000 ms, TE=2.92 ms, TI1=700 ms, TI2=2500 ms, FA1=4°, FA2=5°, pre-scan normalization, echo spacing=6.9 ms, bandwidth=240 Hz/pixel, FOV=256 mm, voxel size= 1 mm isotropic, GRAPPA acceleration factor 3, slice order=interleaved, duration=8 min 22 s | acq-mp2rage_T1w, acq-mp2rage_T1map, acq-mp2rage_defacemask, inv-1_mp2rage,inv-2_mp2rage | acq-mp2rage_brain |
| T2-weighted | Sagittal acquisition orientation, one 3D volume with 176 slices, TR=3200 ms, TE=409 ms, FA=variable, pre-scan normalization, echo spacing=3.42 ms, bandwidth=751 Hz/pixel, FOV=256 mm, voxel size=1 mm isotropic, GRAPPA acceleration factor 2, duration=4 min 43 s | T2w | |
| Fluid-attenuated inversion recovery (FLAIR) 2D (scanned in first 112 participants) | Axial acquisition orientation, 28 slices, TR=10000 ms, TE=90 ms, TI=2500 ms, FA=180°, pre-scan normalization, echo spacing=9.98 ms, bandwidth=199 Hz/pixel, FOV=220 mm, voxel size=0.9×0.9×4.0 mm3, slice order=interleaved, duration=4 min 42 s | acq-lowres_FLAIR | |
| 3D SPACE sequence with fluid-attenuated inversion-recovery preparation (introduced after first 112 participants) | Sagittal acquisition orientation, one 3D volume with 192 slices, TR=5000 ms, TE=395 ms, TI=1800 ms, FA=variable, pre-scan normalization, echo spacing=3.36 ms, bandwidth=781 Hz/pixel, FOV=250 mm, voxel size=1 mm isotropic, GRAPPA acceleration factor 2, duration=7 min 2 s | acq-highres_FLAIR | |
| Diffusion-weighted Imaging (DWI, scanned in first 112 participants) | 88 axial slices, voxel size=1.7 mm isotropic, 60 diffusion-encoding gradient directions, b-value of 1000 s/mm2, 7 non-diffusion-weighted b0 distributed in the sequence, TR=7000 ms, TE=80 ms, FA=90°, bandwidth=1502 Hz/pixel, echo spacing=0.78 ms, FOV=220 mm, voxel dimension=1.7 mm isotropic, imaging matrix=128×128, acquired with ⅞ partial Fourier encoding and GRAPPA (acceleration factor 2, 32 ref. lines), 60 diffusion-encoding gradient directions, b-value=1000 s/mm2, 7 b0 images, raw data filter, fat suppression (strong), advanced shim mode, no prescan normalization, interleaved acquisition, CMRR sequence, monopolar diffusion scheme, SENSE coil combine, multiband acceleration factor 2, phase encoding A ≫ P, duration=9 min 27 s | dwi | |
| Spin echo images with reversed phase encoding for DWI distortion correction (scanned in first 112 participants) | Two volumes with A ≫ P and P ≫ A phase encoding, voxel size=1.7 mm isotropic, 88 axial slices, TR=7000 ms, TE=80 ms, FA=90°, bandwidth=1502 Hz/pixel, echo spacing 0.78 ms, FOV=220 mm, voxel dimension=1.7 mm isotropic, imaging matrix=128×128, acquired with ⅞ partial Fourier encoding and GRAPPA (acceleration factor 2, 32 ref. lines), fat suppression (strong), advanced shim mode, no prescan normalization, interleaved acquisition, CMRR sequence, SENSE coil combine, multiband acceleration factor 2, duration=1 min 59 s each | acq-SEfmapDWI_dir-AP_epi, acq-SEfmapDWI_dir-PA_epi | |
| Diffusion-weighted Imaging (DWI, new version introduced after first 112 participants) | 88 axial slices, voxel size=1.7 mm isotropic, 60 diffusion-encoding gradient directions, b-value of 1000 s/mm2, 7 non-diffusion-weighted b0 distributed in the sequence, TR=7000 ms, TE=80 ms, FA=90°, bandwidth=1502 Hz/pixel, echo spacing=0.78 ms, FOV=220 mm, voxel dimension=1.7 mm isotropic, imaging matrix=128×128, acquired with ⅞ partial Fourier encoding and GRAPPA (acceleration factor 2, 32 ref. lines), 60 diffusion-encoding gradient directions, b-value=1000 s/mm2, 7 b0 images, raw data filter, fat suppression, advanced shim mode, no prescan normalization, interleaved acquisition, CMRR sequence, monopolar diffusion scheme, SENSE coil combine, multiband acceleration factor 2, phase encoding A ≫ P, duration=8 min 38 s | dwi | |
| Spin echo images with reversed phase encoding for DWI distortion correction (new version introduced after first 112 participants) | Two volumes with A ≫ P and P ≫ A phase encoding, voxel size=1.7 mm isotropic, 88 axial slices, TR=7000 ms, TE=80 ms, FA=90°, bandwidth=1502 Hz/pixel, echo spacing 0.78 ms, FOV=220 mm, voxel dimension=1.7 mm isotropic, imaging matrix=128×128, acquired with ⅞ partial Fourier encoding and GRAPPA (acceleration factor 2, 32 ref. lines), fat suppression, advanced shim mode, no prescan normalization, interleaved acquisition, CMRR sequence, SENSE coil combine, multiband acceleration factor 2, duration=1 min 10 s each | acq-SEfmapDWI_dir-AP_epi, acq-SEfmapDWI_dir-PA_epi | |
| Gradient echo Susceptibility-weighted data for SWI and QSM estimation (introduced after first 112 participants) | Axial acquisition orientation, one 3D volume with 160 slices, TR=30 ms, TE=17.3 ms, FA=13°, bandwidth=150 Hz/pixel, FOV=205 mm, acquired with 6/8 phase partial Fourier and GRAPPA (acceleration factor 2, 24 ref. lines), no prescan normalization, interleaved acquisition, voxel size=0.8 mm isotropic, duration=7 min 50 s | acq-phase_GRE, acq-mag_GRE |
Figure 2Quality assessment of resting-state fMRI scans.
Distribution of motion (maximum and mean framewise displacement).